Compare LSF & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSF | PDSB |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 42.4M |
| IPO Year | 2020 | 2015 |
| Metric | LSF | PDSB |
|---|---|---|
| Price | $2.90 | $1.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $7.17 | $4.75 |
| AVG Volume (30 Days) | 21.3K | ★ 32.0M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,889,286.00 | N/A |
| Revenue This Year | $188.00 | N/A |
| Revenue Next Year | $32.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $1.96 | $0.20 |
| 52 Week High | $5.59 | $1.55 |
| Indicator | LSF | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 26.32 | 76.55 |
| Support Level | $2.40 | $0.60 |
| Resistance Level | $3.59 | $1.55 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 1.72 | 96.30 |
Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.